Sun Z-J, Du X, Su L-L, Zhang X-D, Wang W
Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China.
Department of Urology, Beijing Chaoyang Hospital Affiliated with Capital Medical University, Beijing, China.
Transplant Proc. 2015 Oct;47(8):2439-45. doi: 10.1016/j.transproceed.2015.08.009.
Interleukin-2 receptor antagonists (IL-2RAs) have been extensively used in kidney transplant patients to prevent the occurrence of acute rejection. The efficacy and safety of basiliximab and daclizumab, the 2 most commonly used IL-2RAs in clinics, have been compared in a number of randomized controlled trials, but no definite conclusions have been drawn.
This meta-analysis aimed to compare the efficacy and safety of basiliximab and daclizumab in kidney transplant patients.
We performed keyword searches in Pubmed, Embase, and the Cochrane library. In total, 6 randomized controlled trials with 509 patients were included in this meta-analysis. Data collected included patient survival, graft survival, acute rejection, infection, and cytomegalovirus infection. The outcome measure was the relative risk of basiliximab versus daclizumab.
Therapy with basiliximab and daclizumab resulted in similar outcomes regarding acute rejection (6-month 95% confidence interval [CI], 0.09-1.14; 12-month 95% CI, 0.53-1.91), patient survival (95% CI, 0.97-1.04), graft survival (95% CI, 0.98-1.08), infection (95% CI, 0.66-1.01), and cytomegalovirus infection (95% CI, 0.45-1.14) within the follow-up period. There were no significant differences in safety and efficacy between the 2 drugs.
The safety and efficacy of daclizumab and basiliximab are similar in kidney transplant recipients.
白细胞介素-2受体拮抗剂（IL-2RAs）已广泛应用于肾移植患者以预防急性排斥反应的发生。巴利昔单抗和达利珠单抗是临床上最常用的两种IL-2RAs，多项随机对照试验对二者的疗效和安全性进行了比较，但尚未得出明确结论。
本荟萃分析旨在比较巴利昔单抗和达利珠单抗在肾移植患者中的疗效和安全性。
我们在PubMed、Embase和Cochrane图书馆进行了关键词搜索。本荟萃分析共纳入6项随机对照试验，涉及509例患者。收集的数据包括患者生存率、移植物生存率、急性排斥反应、感染和巨细胞病毒感染。结局指标是巴利昔单抗与达利珠单抗的相对风险。
在随访期内，巴利昔单抗和达利珠单抗治疗在急性排斥反应（6个月95%置信区间[CI]，0.09 - 1.14；12个月95% CI，0.53 - 1.91）、患者生存率（95% CI，0.97 - 1.04）、移植物生存率（95% CI，0.98 - 1.08）、感染（95% CI，0.66 - 1.01）和巨细胞病毒感染（95% CI，0.45 - 1.14）方面的结果相似。两种药物在安全性和疗效方面无显著差异。
在肾移植受者中，达利珠单抗和巴利昔单抗的安全性和疗效相似。
